Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Income from Continuing Operations (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Income from Continuing Operations for 5 consecutive years, with 9782844.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Income from Continuing Operations fell 33.36% year-over-year to 9782844.0, compared with a TTM value of 37411051.0 through Jun 2025, up 7.22%, and an annual FY2025 reading of 47761995.0, down 13.87% over the prior year.
  • Income from Continuing Operations was 9782844.0 for Q2 2025 at SAB Biotherapeutics, up from 9943342.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1409834.0 in Q1 2021 and bottomed at 22856763.0 in Q4 2023.
  • Average Income from Continuing Operations over 5 years is 7087664.0, with a median of 7076068.0 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations crashed 845.93% in 2023, then surged 56.5% in 2024.
  • Year by year, Income from Continuing Operations stood at 11551496.0 in 2021, then soared by 32.05% to 7848975.0 in 2022, then plummeted by 191.21% to 22856763.0 in 2023, then skyrocketed by 56.5% to 9943342.0 in 2024, then grew by 1.61% to 9782844.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for SABS at 9782844.0 in Q2 2025, 9943342.0 in Q4 2024, and 10349410.0 in Q3 2024.